Gout and Other Crystal Arthropathies
Özet
Inflammation facilitates both atherogenesis and thrombogenesis in the development of coronary artery disease. Chronic inflammation in any part of the body initiates atherosclerosis and creates a prothrombotic environment. Mortality and the incidence of complications from atherosclerosis are increased in chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and gout. There are observations regarding the association between gout and risk factors for atherosclerosis. The risk of atherosclerotic disease is increased in patients with gout. Several epidemiological studies showed a positive relationship between the risk of cardiovascular disease and elevated serum uric acid levels. However, asymptomatic hyperuricemia has not been proven as an independent risk factor for atherosclerosis. Although the underlying mechanisms are not well understood, hyperuricemia is associated with many cardiovascular risk factors such as hypertension, obesity, insulin resistance and hyperlipidemia. Therefore, screening and treatment of cardiovascular risk factors are important in patients with gout.
İnflamasyon, aterogeneze ve trombogeneze neden olarak koroner arter hastalığının gelişimini kolaylaştırır. Vücudun herhangi bir yerindeki kronik inflamasyon aterosklerozu başlatır ve protrombotik bir ortam yaratır. Romatoid artrit, sistemik lupus eritematozus ve gut gibi kronik inflamatuar hastalıklarda aterosklerozdan kaynaklanan komplikasyonlar ve mortalite artar. Gut hastalarında aterosklerotik hastalık riski artmaktadır. Çeşitli epidemiyolojik çalışmalar, kardiyovasküler hastalık riski ile yüksek serum ürik asit seviyeleri arasında pozitif bir ilişki olduğunu göstermiştir. Bununla birlikte, asemptomatik hiperüriseminin ateroskleroz için bağımsız bir risk faktörü olduğu kanıtlanmamıştır. Altta yatan mekanizmalar tam olarak anlaşılamamış olsa da hiperürisemi, hipertansiyon, obezite, insülin direnci ve hiperlipidemi gibi birçok KV risk faktörü ile ilişkilidir. Gut hastalığı olan hastalarda KV risk faktörleri taranmalı ve tedavisi yapılmalıdır.
Referanslar
Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105;1135-43.
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
Tiong AY, Brieger D. Inflammation and coronary artery disease. American Heart Jurnal 2005;150:11-8.
Abbott RD, Brand FN, Kannel WB et al. Gout and coronary heart disease: the Framingham Study. Journal of Clinical Epidemiology 1988;41:237-42.
Frang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study,1971-1992. Journal of American Medical Association 2000;10;283:2404-10.
Wannamethee SG, Shaper AG, Whincup PH. Serum urat and risk of major coronary heart disease events. Heart 1997,78:147-53.
Lottmann K, Chen X, Schädlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Current Rheumatology Reports 2012; 14: 195–203.
Peter Cox, Sonal Gupta, Sizheng Steven Zhao et al. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta‑analysis. Rheumatology International 2021 41:1209–1219. https://doi.org/10.1007/s00296-021-04876-6
Janssens HJ, Arts PG, Schalk BW et al. Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: a primary care retrospective cohort study. Joint Bone Spine 2017; 84: 59–64.
Disveld IJM, Fransen J, Rongen GA, et al. Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease. Journal of Rheumatology 2018; 45: 858–63.
Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Research Therapy 2006;8 Suppl 1:S2.
Pascual E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheumatology 1991;34:141-5.
Daria B. Crittenden, R. Aaron Lehmann, Laura Schneck, Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout. Journal of Rheumatology. 2012 July ; 39(7): 1458–1464. doi:10.3899/jrheum.111533.
Muhammad U. Siddiqui, Joey Junarta, Swaminathan Sathyanarayanan et al. Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. IJC Heart & Vasculature 45 2023 101191.
Grimaldi-Bensouda L, Alpérovitch A, Aubrun E et al. the PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Annals of the Rheumatic Diseases 2015 May;74(5):836-42 doi: 10.1136/annrheumdis-2012-202972
Markus Bredemeier, Lediane Moreira Lopes , Matheus Augusto Eisenreich et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. Bredemeier et al. BMC Cardiovascular Disorders 2018 18:24. DOI 10.1186/s12872-018-0757-9
Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched cohort study. PLoS One. 2014;9(6):e99102.
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine 2018; 378: 1200–10.
Isla S Mackenzie , Ian Ford , George Nuki et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0.
Barrientos-Regala, Marie, Macabeo, Renelene A, Ramirez-Ragasa, Rosemarie et al. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis. Journal of Cardiovascular Pharmacology 76(4):p 461-471, October 2020. DOI: 10.1097/FJC.0000000000000871.
Nakazono K, Watanebe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-8.
White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, et al. Superoxide and peroxynitrite in atherosclerosis. The Proceedings of the National Academy of Sciences USA 1994;91:1044-8.
Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell prolferation by increasing platelet-derived growth factor A-chain expression. Journal of Biological Chemistry 1991;266:8604-8.
Ginsberg MH, Kozin F, O’Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. The Journal of Clinical Investigation 1997;60:999-1007.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.
Nagakawa T, Mazzali M, Kang D-H, Kanellis J, Watanabe S, Sanchez-Lozada LG, et al. Hyperuricemia causes glomerular hypertrophy in the rat. American Journal of Nephrology 2003;23:2-7.
Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and White adults: The CARDIA study. Annals of Epidemiology 1998;8:250-61.
Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and insulin sensitivity index in a population-based sample of 380 young healthy caucasians. European Journal of Endocrinology 1998;138:63-9.
Waring WS, Webb DJ, Maxwell SRJ. Uric acid as a risk factor for cardiovascular disease. Oxford Journal of Medicine 2000;93:707-13.
Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Archives of Internal Medicine 2005;165(7):742-8.
Fam AG. Gout, diet, and the insulin resistance syndrome. Journal of Rheumatology 2002;29:1350-5.
Liang CW, Islam MM, Poly TN, Yang HC, Jack Li YC. Association between gout and cardiovascular disease risk: a nation-wide case-control study. Joint Bone Spine 2019;86:389–91.
Disveld IJM, Zoakman S, Jansen T, Rongen GA, Kienhorst LBE, Janssens H, et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clinical Rheumatology 2019;38:1385–91.
Andres M, Bernal JA, Sivera F, Quilis N, Carmona L, Vela P, et al. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Annals of Rheumatic Diseases 2017;76:1263–8.
Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with Gout. JAMA Cardiolology 2019;4:1019–28.
36.Mary A. De Vera, MSc, M Mushfiqur Rahman, MSc, Vidula Bhole, MD, MHSc et al. The Independent Impact of Gout on the Risk of Acute Myocardial Infarction Among Elderly Women: A Population-Based Study. Annals of Rheumatic Diseases. 2010 June;69(6):1162–1164. doi:10.1136/ard.2009.122770.
Qinglin Wu Chuangong Fu Zhifu Lu. The risk of myocardial infarction and heart failure in patients with gouty arthritis: A systematic review and meta-analysis. International Journal Rheumatic Diseases. 2023;26:415–424.
Jing-Chi Lin, Chun-Liang Lin, Mien-Cheng Chen et al. Gout, not hyperuricemia alone, impairs left ventricular diastolic function. Arthritis Research & Therapy 2015 17:323 DOI 10.1186/s13075-015-0842-8
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007_2008. American Journal of Medicine 2012;125:679–87 e1.
Borghi C, Agnoletti D, Cicero AFG, Lurbe E, Virdis A. Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk. Hypertension. 2022 Sep;79(9):1927-1936. doi: 10.1161/HYPERTENSIONAHA.122.17956.
Cowley S, McCarthy G. Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review. Open Access Rheumatol. 2023 Mar 22;15:33-41. doi: 10.2147/OARRR.S389664.
Maaman Bashir, Katherine A. Sherman, Daniel H. Solomon et al. Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease: A Nationwide Study of Veterans. Arthritis Care & Research Vol. 75, No. 2, February 2023, pp 277–282 DOI 10.1002/acr.24783
Sara K. Tedeschi, Weixing Huang, Kazuki Yoshida et al. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. Annals of Rheumatic Diseases. 2022 May 25: 2022-222387. doi: 10.1136/annrheumdis-2022-222387
